Jane Street Group LLC Acquires Shares of 11,141 XBiotech Inc. (NASDAQ:XBIT)

Jane Street Group LLC bought a new stake in XBiotech Inc. (NASDAQ:XBIT) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 11,141 shares of the biopharmaceutical company’s stock, valued at approximately $86,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its holdings in XBiotech by 102.9% in the second quarter. Bank of New York Mellon Corp now owns 98,314 shares of the biopharmaceutical company’s stock valued at $505,000 after acquiring an additional 49,863 shares during the last quarter. Rhumbline Advisers lifted its position in XBiotech by 2,568.5% during the 2nd quarter. Rhumbline Advisers now owns 20,094 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 19,341 shares during the period. American Century Companies Inc. bought a new position in shares of XBiotech in the 2nd quarter valued at about $393,000. Charles Schwab Investment Management Inc. grew its position in shares of XBiotech by 7.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 58,437 shares of the biopharmaceutical company’s stock worth $452,000 after buying an additional 4,298 shares during the period. Finally, FMR LLC raised its stake in shares of XBiotech by 34.4% during the third quarter. FMR LLC now owns 28,992 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 7,420 shares during the last quarter. Institutional investors own 55.70% of the company’s stock.

XBiotech Price Performance

Shares of NASDAQ XBIT opened at $3.71 on Wednesday. XBiotech Inc. has a fifty-two week low of $3.51 and a fifty-two week high of $9.96. The firm has a market capitalization of $113.09 million, a P/E ratio of -3.44 and a beta of 1.44. The company’s 50 day simple moving average is $5.95 and its 200 day simple moving average is $6.49.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.